The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson’s disease: opicapone versus entacapone

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
Online-Ressource, 1 online resource.
Language
Englisch

Bibliographic citation
The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson’s disease: opicapone versus entacapone ; volume:130 ; number:7 ; day:10 ; month:4 ; year:2023 ; pages:925-930 ; date:7.2023
Journal of neural transmission ; 130, Heft 7 (10.4.2023), 925-930, 7.2023

Creator
Leta, Valentina
Wamelen, Daniel J. van
Aureli, Federico
Metta, Vinod
Trivedi, Dhaval
Cortelli, Pietro
Rodriguez-Blazquez, Carmen
Rizos, Alexandra
Chaudhuri, K. Ray
Contributor
SpringerLink (Online service)

DOI
10.1007/s00702-023-02603-y
URN
urn:nbn:de:101:1-2023092710294620473521
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
2025-08-14T10:58:53+0200

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Leta, Valentina
  • Wamelen, Daniel J. van
  • Aureli, Federico
  • Metta, Vinod
  • Trivedi, Dhaval
  • Cortelli, Pietro
  • Rodriguez-Blazquez, Carmen
  • Rizos, Alexandra
  • Chaudhuri, K. Ray
  • SpringerLink (Online service)

Other Objects (12)

Gender differences in non-motor fluctuations in Parkinson’s disease

Gender differences in non-motor fluctuations in Parkinson’s disease

Non-motor symptoms in newly diagnosed Parkinson’s disease patients

Non-motor symptoms in newly diagnosed Parkinson’s disease patients

Screening for non-motor symptoms in Egyptian patients with Parkinson’s disease

Screening for non-motor symptoms in Egyptian patients with Parkinson’s disease

NMDA antagonists for treating the non-motor symptoms in Parkinson’s disease

NMDA antagonists for treating the non-motor symptoms in Parkinson’s disease

Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson’s disease

Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson’s disease

Modulatory Effects of Levodopa on Cerebellar Connectivity in Parkinson’s Disease

Modulatory Effects of Levodopa on Cerebellar Connectivity in Parkinson’s Disease

Gut bacterial deamination of residual levodopa medication for Parkinson’s disease

Gut bacterial deamination of residual levodopa medication for Parkinson’s disease

Embelin and levodopa combination therapy for improved Parkinson’s disease treatment

Embelin and levodopa combination therapy for improved Parkinson’s disease treatment

Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease

Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease

Motor and non-motor outcomes in patients with advanced Parkinson’s disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study

Motor and non-motor outcomes in patients with advanced Parkinson’s disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study

Microstructure predicts non-motor outcomes following deep brain stimulation in Parkinson’s disease

Microstructure predicts non-motor outcomes following deep brain stimulation in Parkinson’s disease

Nonmotor symptom burden grading as predictor of cognitive impairment in Parkinson’s disease

Nonmotor symptom burden grading as predictor of cognitive impairment in Parkinson’s disease

Related objects